Research programme: varicella zoster vaccine - Novavax

Drug Profile

Research programme: varicella zoster vaccine - Novavax

Alternative Names: Shingles vaccine - Novavax; Varicella zoster virus (VZV) vaccine - Novavax; VZV VLP vaccine - Novavax

Latest Information Update: 09 Oct 2013

Price : $50

At a glance

  • Originator Novavax
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Varicella zoster virus infections

Most Recent Events

  • 09 Oct 2013 No development reported - Preclinical for Varicella zoster virus infections (prevention) in USA (Parenteral)
  • 19 Sep 2007 Early research in Varicella zoster virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top